Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/SB-742457> ?p ?o }
Showing triples 1 to 83 of
83
with 100 triples per page.
- SB-742457 abstract "SB-742457 (RVT-101) is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects. It was under development by GlaxoSmithKline for the treatment of Alzheimer's disease and demonstrated some preliminary efficacy in phase II clinical trials; however, GSK chose not to continue development and sold the rights to Axovant Sciences in December 2014.".
- SB-742457 atcPrefix "none".
- SB-742457 casNumber "607742-69-8".
- SB-742457 fdaUniiCode "2IOB2M82HY".
- SB-742457 iupacName "3-Phenylsulfonyl-8-(piperazin-1-yl)quinoline".
- SB-742457 pubchem "11256720".
- SB-742457 thumbnail SB-742457-structure.png?width=300.
- SB-742457 wikiPageID "26482995".
- SB-742457 wikiPageLength "4576".
- SB-742457 wikiPageOutDegree "14".
- SB-742457 wikiPageRevisionID "686926083".
- SB-742457 wikiPageWikiLink 5-HT6_receptor.
- SB-742457 wikiPageWikiLink Alzheimers_disease.
- SB-742457 wikiPageWikiLink Axovant_Sciences.
- SB-742457 wikiPageWikiLink Binding_selectivity.
- SB-742457 wikiPageWikiLink Category:Piperazines.
- SB-742457 wikiPageWikiLink Category:Quinolines.
- SB-742457 wikiPageWikiLink Category:Sulfones.
- SB-742457 wikiPageWikiLink Clinical_trial.
- SB-742457 wikiPageWikiLink Cognition.
- SB-742457 wikiPageWikiLink GlaxoSmithKline.
- SB-742457 wikiPageWikiLink Learning.
- SB-742457 wikiPageWikiLink Memory.
- SB-742457 wikiPageWikiLink Receptor_antagonist.
- SB-742457 wikiPageWikiLinkText "SB-742457".
- SB-742457 atcPrefix "none".
- SB-742457 c "19".
- SB-742457 casNumber "607742".
- SB-742457 chembl "1083390".
- SB-742457 chemspiderid "9431746".
- SB-742457 h "19".
- SB-742457 inchi "1".
- SB-742457 inchikey "JJZFWROHYSMCMU-UHFFFAOYAZ".
- SB-742457 iupacName "3".
- SB-742457 legalStatus "Investigational".
- SB-742457 molecularWeight "353.44".
- SB-742457 n "3".
- SB-742457 o "2".
- SB-742457 pubchem "11256720".
- SB-742457 routesOfAdministration "Oral".
- SB-742457 s "1".
- SB-742457 smiles "C3CNCCN3c1cccccc4Sc2ccccc2".
- SB-742457 stdinchi "1".
- SB-742457 stdinchikey "JJZFWROHYSMCMU-UHFFFAOYSA-N".
- SB-742457 unii "2".
- SB-742457 verifiedfields "changed".
- SB-742457 verifiedrevid "451551710".
- SB-742457 wikiPageUsesTemplate Template:Antidementia.
- SB-742457 wikiPageUsesTemplate Template:Cascite.
- SB-742457 wikiPageUsesTemplate Template:Chemspidercite.
- SB-742457 wikiPageUsesTemplate Template:Drugbox.
- SB-742457 wikiPageUsesTemplate Template:Ebicite.
- SB-742457 wikiPageUsesTemplate Template:Fdacite.
- SB-742457 wikiPageUsesTemplate Template:Nervous-system-drug-stub.
- SB-742457 wikiPageUsesTemplate Template:Nootropics.
- SB-742457 wikiPageUsesTemplate Template:Piperazines.
- SB-742457 wikiPageUsesTemplate Template:Reflist.
- SB-742457 wikiPageUsesTemplate Template:Serotonergics.
- SB-742457 wikiPageUsesTemplate Template:Stdinchicite.
- SB-742457 subject Category:Piperazines.
- SB-742457 subject Category:Quinolines.
- SB-742457 subject Category:Sulfones.
- SB-742457 hypernym Antagonist.
- SB-742457 type ChemicalSubstance.
- SB-742457 type Drug.
- SB-742457 type Group.
- SB-742457 type Chemical.
- SB-742457 type Drug.
- SB-742457 type Group.
- SB-742457 type Heterocycle.
- SB-742457 type ChemicalObject.
- SB-742457 type Thing.
- SB-742457 type Q8386.
- SB-742457 comment "SB-742457 (RVT-101) is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects. It was under development by GlaxoSmithKline for the treatment of Alzheimer's disease and demonstrated some preliminary efficacy in phase II clinical trials; however, GSK chose not to continue development and sold the rights to Axovant Sciences in December 2014.".
- SB-742457 label "SB-742457".
- SB-742457 sameAs Q855449.
- SB-742457 sameAs m.0bbx1rs.
- SB-742457 sameAs SB-742,457.
- SB-742457 sameAs SB-742,457.
- SB-742457 sameAs Q855449.
- SB-742457 wasDerivedFrom SB-742457?oldid=686926083.
- SB-742457 depiction SB-742457-structure.png.
- SB-742457 isPrimaryTopicOf SB-742457.